Characterization of CD8 + T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions
Open Access
- 18 January 2021
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 1870062
Abstract
CD8+ T cells are capable of recognizing mutation-derived neoantigens displayed by HLA class I molecules, thereby exhibiting the ability to distinguish between cancer and normal cells. However, accumulating evidence has shown that only a small fraction of nonsynonymous somatic mutations give rise to clinically relevant neoantigens. The properties of such neoantigens, which must be presented by HLA and immunogenic to induce a T-cell response, remain elusive. In this study, we explored the HLA class I ligandome of a human cancer cell line with microsatellite instability using a proteogenomic approach. The results demonstrated that neoantigens accounted for only 0.34% of the HLA class I ligandome, and most neoantigens were encoded by genes with abundant expression. Thereafter, T-cell responses were prioritized, and immunodominant neoantigens were defined using naive CD8+ T cells derived from healthy donors. AKF9, an immunogenic neoantigen with a mutation at a non-anchor position, formed a stable peptide-HLA complex. T-cell responses were analyzed against a panel of AKF9 variants with single amino-acid substitutions, in which mutations did not alter the high HLA-binding affinity and stability. The responses varied across individuals, demonstrating the impact of heterogeneous T-cell repertoires in this human cancer model. Moreover, responses were biased toward a variant group with large structural changes compared to the wild-type peptide. Thus, naive T-cell induction can be attributed to multiple determinants. Combining structural dissimilarity with gene-expression levels, HLA-binding affinity, and stability may further help prioritize the immunogenicity of non-anchor-type neoantigens.Keywords
Funding Information
- This work was supported by the
- Japan Agency for Medical Research and Development (JP19cm0106352)
- Japan Society for the Promotion of Science
- Japan Society for the Promotion of Science (JP19094976)
- Japan Society for the Promotion of Science (JP20240606)
- Takeda Science Foundation
This publication has 63 references indexed in Scilit:
- HLA-Binding Properties of Tumor Neoepitopes in HumansCancer Immunology Research, 2014
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsNature Medicine, 2013
- Conditional ligands for Asian HLA variants facilitate the definition of CD8+T‐cell responses in acute and chronic viral diseasesEuropean Journal of Immunology, 2012
- Biochemical Large-Scale Identification of MHC Class I Ligands2012
- Why must T cells be cross-reactive?Nature Reviews Immunology, 2012
- Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicityEuropean Journal of Immunology, 2012
- Rosetta FlexPepDock web server—high resolution modeling of peptide–protein interactionsNucleic Acids Research, 2011
- Cytotoxic T Lymphocytes Efficiently Recognize Human Colon Cancer Stem-Like CellsThe American Journal of Pathology, 2011
- COMPARISON OF SPEEDY PCR-SSP METHOD AND SEROLOGICAL TYPING OF HLA-A24 FOR JAPANESE CANCER PATIENTSJournal of Immunoassay and Immunochemistry, 2011
- Generation of peptide–MHC class I complexes through UV-mediated ligand exchangeNature Protocols, 2006